Advertisement
Interested parties can access a live audio webcast and accompanying slidepresentation via the Internet by visiting the Investor Relations section ofthe Company's Web site at http://www.halozyme.com. Archived presentationswill be available on the Web site for 30 days following the presentation.
Advertisement
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializingproducts based on the extracellular matrix for the drug delivery, oncology,and dermatology markets. The company's portfolio of products is based onintellectual property covering the family of human enzymes known ashyaluronidases. The company's Enhanze(TM) Technology is a novel drug deliveryplatform designed to increase the absorption and dispersion of biologics. Itsfirst partnership is with Roche to apply Enhanze Technology to Roche'sbiological therapeutic compounds for up to 13 targets. In addition, thecompany has received FDA approval for two products: Cumulase(R) and HYLENEX,for use as an adjuvant to increase the absorption and dispersion of otherinjected drugs and fluids. HYLENEX is partnered with Baxter HealthcareCorporation. The Company also has a number of different enzymes in itsportfolio that are targeting significant areas of unmet need.Halozyme Contact Investor Relations Contact David A. Ramsay Don Markley Chief Financial Officer Lippert/Heilshorn & Associates (858) 794-8881 (310) 691-7100 [email protected] [email protected]
SOURCE Halozyme Therapeutics, Inc.
